The global market for Hormonal Therapy for Cancer was valued at US$ 16521 million in the year 2024 and is projected to reach a revised size of US$ 38042 million by 2031, growing at a CAGR of 13.2% during the forecast period.

Hormonal Therapy for Cancer Market

Hormonal therapy for cancer is a class of treatments that modulate endocrine signaling to inhibit or block the growth of hormone-dependent tumors. Approaches include suppressing hormone synthesis, blocking hormone receptors, and using receptor modulators; these are widely applied in estrogen- or androgen-sensitive cancers such as breast and prostate cancer. Hormonal therapy may be used as adjuvant treatment in early-stage disease to reduce recurrence risk, and as long-term maintenance or symptom-control therapy in advanced or metastatic settings. Recent advances in molecular subtyping, companion diagnostics, and combination regimens have elevated the role of hormonal therapies within precision oncology, prompting pharmaceutical firms to invest more in drug optimization, label expansion, and co-development with other targeted or immune agents—creating fresh commercialization and value-chain integration opportunities.

Hormonal therapy for cancer is at an inflection point, shifting from traditional mono-therapy maintenance to precision-guided and combination strategies. Annual reports from major pharmaceutical firms emphasize that label expansion, companion diagnostics, and combinations with novel small molecules or biologics can convert long-standing hormonal platforms into higher-value clinical solutions. Regulators’ increasing focus on biomarker-driven indications and combination regimens—including expedited review pathways in some jurisdictions—provides policy support for faster clinical adoption. Meanwhile, capital markets and M&A activity favor platform companies with expandable treatment lines and robust clinical evidence, concentrating resources on projects with combination potential and diagnostic capabilities, thereby accelerating innovation and commercialization.

Opportunities come with material uncertainty. Combination regimens and indication expansions require lengthy clinical validation and complex regulatory pathways, increasing upfront investment and time to market. Annual reports and regulatory notices highlight risks from patent expiries, generic competition, and reimbursement policy shifts that can disrupt established revenue models. Furthermore, commercialization of companion diagnostics demands cross-sector collaboration (pharma, diagnostics, clinical services); delays or mismatches in any link can slow overall launch. Thus, while pursuing efficacy and differentiation, firms must concurrently manage R&D, compliance, and supply-chain pressures.

Downstream demand is evolving from outcome-centric to continuity-and-connectivity-centric. Clinicians now evaluate hormonal regimens not only for efficacy and safety, but also for long-term management convenience and integration with imaging and molecular testing. Pharma partnerships with clinical research organizations and diagnostics firms on companion assays and real-world evidence generation are intensifying, shifting commercial models from pure product supply toward service-oriented platforms. For marketing and investor audiences, companies that can demonstrate an end-to-end value chain—from drug to diagnostic to follow-up—are more likely to capture procurement and capital attention.

The upstream ecosystem for hormonal therapies and related combination products includes active pharmaceutical ingredients (APIs), advanced formulation excipients and delivery technologies, and molecular reagents for companion diagnostics. Annual reports indicate that global supply availability, consistent quality, and regulatory compliance of key APIs and diagnostic reagents critically impact the ability to scale production and enter new markets rapidly. In the face of geopolitical and trade policy volatility, firms that achieve regionalized sourcing or upstream self-sufficiency will realize durable advantages in cost, delivery reliability, and compliance—foundations that underpin downstream commercialization.

This report aims to provide a comprehensive presentation of the global market for Hormonal Therapy for Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hormonal Therapy for Cancer.

The Hormonal Therapy for Cancer market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Hormonal Therapy for Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Hormonal Therapy for Cancer companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Hormonal Therapy for Cancer Market Report

Report Metric	Details
Report Name	Hormonal Therapy for Cancer Market
Accounted market size in year	US$ 16521 million
Forecasted market size in 2031	US$ 38042 million
CAGR	13.2%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Tablet Capsule Injection Others
Segment by Application	Hospital Retail Pharmacy Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	GlaxoSmithKline, Jiangsu Haosen, Sun Pharmaceutical, Hengrui Medical, Dr Reddy's Laboratories, Astellas Pharma, Sumitomo Pharma, Johnson & Johnson, Bayer AG, Pfizer, AstraZeneca, Novartis, Ferring Pharmaceuticals, Myovant Sciences
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hormonal Therapy for Cancer company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Hormonal Therapy for Cancer Market growing?

Ans: The Hormonal Therapy for Cancer Market witnessing a CAGR of 13.2% during the forecast period 2025-2031.

What is the Hormonal Therapy for Cancer Market size in 2031?

Ans: The Hormonal Therapy for Cancer Market size in 2031 will be US$ 38042 million.

Who are the main players in the Hormonal Therapy for Cancer Market report?

Ans: The main players in the Hormonal Therapy for Cancer Market are GlaxoSmithKline, Jiangsu Haosen, Sun Pharmaceutical, Hengrui Medical, Dr Reddy's Laboratories, Astellas Pharma, Sumitomo Pharma, Johnson & Johnson, Bayer AG, Pfizer, AstraZeneca, Novartis, Ferring Pharmaceuticals, Myovant Sciences

What are the Application segmentation covered in the Hormonal Therapy for Cancer Market report?

Ans: The Applications covered in the Hormonal Therapy for Cancer Market report are Hospital, Retail Pharmacy, Other

What are the Type segmentation covered in the Hormonal Therapy for Cancer Market report?

Ans: The Types covered in the Hormonal Therapy for Cancer Market report are Tablet, Capsule, Injection, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Hormonal Therapy for Cancer Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Tablet

1.2.3 Capsule

1.2.4 Injection

1.2.5 Others

1.3 Market by Application

1.3.1 Global Hormonal Therapy for Cancer Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospital

1.3.3 Retail Pharmacy

1.3.4 Other

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Hormonal Therapy for Cancer Market Perspective (2020-2031)

2.2 Global Hormonal Therapy for Cancer Growth Trends by Region

2.2.1 Global Hormonal Therapy for Cancer Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Hormonal Therapy for Cancer Historic Market Size by Region (2020-2025)

2.2.3 Hormonal Therapy for Cancer Forecasted Market Size by Region (2026-2031)

2.3 Hormonal Therapy for Cancer Market Dynamics

2.3.1 Hormonal Therapy for Cancer Industry Trends

2.3.2 Hormonal Therapy for Cancer Market Drivers

2.3.3 Hormonal Therapy for Cancer Market Challenges

2.3.4 Hormonal Therapy for Cancer Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Hormonal Therapy for Cancer Players by Revenue

3.1.1 Global Top Hormonal Therapy for Cancer Players by Revenue (2020-2025)

3.1.2 Global Hormonal Therapy for Cancer Revenue Market Share by Players (2020-2025)

3.2 Global Top Hormonal Therapy for Cancer Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Hormonal Therapy for Cancer Revenue

3.4 Global Hormonal Therapy for Cancer Market Concentration Ratio

3.4.1 Global Hormonal Therapy for Cancer Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Hormonal Therapy for Cancer Revenue in 2024

3.5 Global Key Players of Hormonal Therapy for Cancer Head office and Area Served

3.6 Global Key Players of Hormonal Therapy for Cancer, Product and Application

3.7 Global Key Players of Hormonal Therapy for Cancer, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Hormonal Therapy for Cancer Breakdown Data by Type

4.1 Global Hormonal Therapy for Cancer Historic Market Size by Type (2020-2025)

4.2 Global Hormonal Therapy for Cancer Forecasted Market Size by Type (2026-2031)

5 Hormonal Therapy for Cancer Breakdown Data by Application

5.1 Global Hormonal Therapy for Cancer Historic Market Size by Application (2020-2025)

5.2 Global Hormonal Therapy for Cancer Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Hormonal Therapy for Cancer Market Size (2020-2031)

6.2 North America Hormonal Therapy for Cancer Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Hormonal Therapy for Cancer Market Size by Country (2020-2025)

6.4 North America Hormonal Therapy for Cancer Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Hormonal Therapy for Cancer Market Size (2020-2031)

7.2 Europe Hormonal Therapy for Cancer Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Hormonal Therapy for Cancer Market Size by Country (2020-2025)

7.4 Europe Hormonal Therapy for Cancer Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific Hormonal Therapy for Cancer Market Size (2020-2031)

8.2 Asia-Pacific Hormonal Therapy for Cancer Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Hormonal Therapy for Cancer Market Size by Region (2020-2025)

8.4 Asia-Pacific Hormonal Therapy for Cancer Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America Hormonal Therapy for Cancer Market Size (2020-2031)

9.2 Latin America Hormonal Therapy for Cancer Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Hormonal Therapy for Cancer Market Size by Country (2020-2025)

9.4 Latin America Hormonal Therapy for Cancer Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Hormonal Therapy for Cancer Market Size (2020-2031)

10.2 Middle East & Africa Hormonal Therapy for Cancer Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Hormonal Therapy for Cancer Market Size by Country (2020-2025)

10.4 Middle East & Africa Hormonal Therapy for Cancer Market Size by Country (2026-2031)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 GlaxoSmithKline

11.1.1 GlaxoSmithKline Company Details

11.1.2 GlaxoSmithKline Business Overview

11.1.3 GlaxoSmithKline Hormonal Therapy for Cancer Introduction

11.1.4 GlaxoSmithKline Revenue in Hormonal Therapy for Cancer Business (2020-2025)

11.1.5 GlaxoSmithKline Recent Development

11.2 Jiangsu Haosen

11.2.1 Jiangsu Haosen Company Details

11.2.2 Jiangsu Haosen Business Overview

11.2.3 Jiangsu Haosen Hormonal Therapy for Cancer Introduction

11.2.4 Jiangsu Haosen Revenue in Hormonal Therapy for Cancer Business (2020-2025)

11.2.5 Jiangsu Haosen Recent Development

11.3 Sun Pharmaceutical

11.3.1 Sun Pharmaceutical Company Details

11.3.2 Sun Pharmaceutical Business Overview

11.3.3 Sun Pharmaceutical Hormonal Therapy for Cancer Introduction

11.3.4 Sun Pharmaceutical Revenue in Hormonal Therapy for Cancer Business (2020-2025)

11.3.5 Sun Pharmaceutical Recent Development

11.4 Hengrui Medical

11.4.1 Hengrui Medical Company Details

11.4.2 Hengrui Medical Business Overview

11.4.3 Hengrui Medical Hormonal Therapy for Cancer Introduction

11.4.4 Hengrui Medical Revenue in Hormonal Therapy for Cancer Business (2020-2025)

11.4.5 Hengrui Medical Recent Development

11.5 Dr Reddy's Laboratories

11.5.1 Dr Reddy's Laboratories Company Details

11.5.2 Dr Reddy's Laboratories Business Overview

11.5.3 Dr Reddy's Laboratories Hormonal Therapy for Cancer Introduction

11.5.4 Dr Reddy's Laboratories Revenue in Hormonal Therapy for Cancer Business (2020-2025)

11.5.5 Dr Reddy's Laboratories Recent Development

11.6 Astellas Pharma

11.6.1 Astellas Pharma Company Details

11.6.2 Astellas Pharma Business Overview

11.6.3 Astellas Pharma Hormonal Therapy for Cancer Introduction

11.6.4 Astellas Pharma Revenue in Hormonal Therapy for Cancer Business (2020-2025)

11.6.5 Astellas Pharma Recent Development

11.7 Sumitomo Pharma

11.7.1 Sumitomo Pharma Company Details

11.7.2 Sumitomo Pharma Business Overview

11.7.3 Sumitomo Pharma Hormonal Therapy for Cancer Introduction

11.7.4 Sumitomo Pharma Revenue in Hormonal Therapy for Cancer Business (2020-2025)

11.7.5 Sumitomo Pharma Recent Development

11.8 Johnson & Johnson

11.8.1 Johnson & Johnson Company Details

11.8.2 Johnson & Johnson Business Overview

11.8.3 Johnson & Johnson Hormonal Therapy for Cancer Introduction

11.8.4 Johnson & Johnson Revenue in Hormonal Therapy for Cancer Business (2020-2025)

11.8.5 Johnson & Johnson Recent Development

11.9 Bayer AG

11.9.1 Bayer AG Company Details

11.9.2 Bayer AG Business Overview

11.9.3 Bayer AG Hormonal Therapy for Cancer Introduction

11.9.4 Bayer AG Revenue in Hormonal Therapy for Cancer Business (2020-2025)

11.9.5 Bayer AG Recent Development

11.10 Pfizer

11.10.1 Pfizer Company Details

11.10.2 Pfizer Business Overview

11.10.3 Pfizer Hormonal Therapy for Cancer Introduction

11.10.4 Pfizer Revenue in Hormonal Therapy for Cancer Business (2020-2025)

11.10.5 Pfizer Recent Development

11.11 AstraZeneca

11.11.1 AstraZeneca Company Details

11.11.2 AstraZeneca Business Overview

11.11.3 AstraZeneca Hormonal Therapy for Cancer Introduction

11.11.4 AstraZeneca Revenue in Hormonal Therapy for Cancer Business (2020-2025)

11.11.5 AstraZeneca Recent Development

11.12 Novartis

11.12.1 Novartis Company Details

11.12.2 Novartis Business Overview

11.12.3 Novartis Hormonal Therapy for Cancer Introduction

11.12.4 Novartis Revenue in Hormonal Therapy for Cancer Business (2020-2025)

11.12.5 Novartis Recent Development

11.13 Ferring Pharmaceuticals

11.13.1 Ferring Pharmaceuticals Company Details

11.13.2 Ferring Pharmaceuticals Business Overview

11.13.3 Ferring Pharmaceuticals Hormonal Therapy for Cancer Introduction

11.13.4 Ferring Pharmaceuticals Revenue in Hormonal Therapy for Cancer Business (2020-2025)

11.13.5 Ferring Pharmaceuticals Recent Development

11.14 Myovant Sciences

11.14.1 Myovant Sciences Company Details

11.14.2 Myovant Sciences Business Overview

11.14.3 Myovant Sciences Hormonal Therapy for Cancer Introduction

11.14.4 Myovant Sciences Revenue in Hormonal Therapy for Cancer Business (2020-2025)

11.14.5 Myovant Sciences Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Dr. Reddy’s Laboratories

Ferring Pharmaceuticals

Myovant Sciences

List of Tables

Table 1. Global Hormonal Therapy for Cancer Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Tablet

Table 3. Key Players of Capsule

Table 4. Key Players of Injection

Table 5. Key Players of Others

Table 6. Global Hormonal Therapy for Cancer Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 7. Global Hormonal Therapy for Cancer Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 8. Global Hormonal Therapy for Cancer Market Size by Region (2020-2025) & (US$ Million)

Table 9. Global Hormonal Therapy for Cancer Market Share by Region (2020-2025)

Table 10. Global Hormonal Therapy for Cancer Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 11. Global Hormonal Therapy for Cancer Market Share by Region (2026-2031)

Table 12. Hormonal Therapy for Cancer Market Trends

Table 13. Hormonal Therapy for Cancer Market Drivers

Table 14. Hormonal Therapy for Cancer Market Challenges

Table 15. Hormonal Therapy for Cancer Market Restraints

Table 16. Global Hormonal Therapy for Cancer Revenue by Players (2020-2025) & (US$ Million)

Table 17. Global Hormonal Therapy for Cancer Market Share by Players (2020-2025)

Table 18. Global Top Hormonal Therapy for Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hormonal Therapy for Cancer as of 2024)

Table 19. Ranking of Global Top Hormonal Therapy for Cancer Companies by Revenue (US$ Million) in 2024

Table 20. Global 5 Largest Players Market Share by Hormonal Therapy for Cancer Revenue (CR5 and HHI) & (2020-2025)

Table 21. Global Key Players of Hormonal Therapy for Cancer, Headquarters and Area Served

Table 22. Global Key Players of Hormonal Therapy for Cancer, Product and Application

Table 23. Global Key Players of Hormonal Therapy for Cancer, Date of Enter into This Industry

Table 24. Mergers & Acquisitions, Expansion Plans

Table 25. Global Hormonal Therapy for Cancer Market Size by Type (2020-2025) & (US$ Million)

Table 26. Global Hormonal Therapy for Cancer Revenue Market Share by Type (2020-2025)

Table 27. Global Hormonal Therapy for Cancer Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 28. Global Hormonal Therapy for Cancer Revenue Market Share by Type (2026-2031)

Table 29. Global Hormonal Therapy for Cancer Market Size by Application (2020-2025) & (US$ Million)

Table 30. Global Hormonal Therapy for Cancer Revenue Market Share by Application (2020-2025)

Table 31. Global Hormonal Therapy for Cancer Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 32. Global Hormonal Therapy for Cancer Revenue Market Share by Application (2026-2031)

Table 33. North America Hormonal Therapy for Cancer Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 34. North America Hormonal Therapy for Cancer Market Size by Country (2020-2025) & (US$ Million)

Table 35. North America Hormonal Therapy for Cancer Market Size by Country (2026-2031) & (US$ Million)

Table 36. Europe Hormonal Therapy for Cancer Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 37. Europe Hormonal Therapy for Cancer Market Size by Country (2020-2025) & (US$ Million)

Table 38. Europe Hormonal Therapy for Cancer Market Size by Country (2026-2031) & (US$ Million)

Table 39. Asia-Pacific Hormonal Therapy for Cancer Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 40. Asia-Pacific Hormonal Therapy for Cancer Market Size by Region (2020-2025) & (US$ Million)

Table 41. Asia-Pacific Hormonal Therapy for Cancer Market Size by Region (2026-2031) & (US$ Million)

Table 42. Latin America Hormonal Therapy for Cancer Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 43. Latin America Hormonal Therapy for Cancer Market Size by Country (2020-2025) & (US$ Million)

Table 44. Latin America Hormonal Therapy for Cancer Market Size by Country (2026-2031) & (US$ Million)

Table 45. Middle East & Africa Hormonal Therapy for Cancer Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 46. Middle East & Africa Hormonal Therapy for Cancer Market Size by Country (2020-2025) & (US$ Million)

Table 47. Middle East & Africa Hormonal Therapy for Cancer Market Size by Country (2026-2031) & (US$ Million)

Table 48. GlaxoSmithKline Company Details

Table 49. GlaxoSmithKline Business Overview

Table 50. GlaxoSmithKline Hormonal Therapy for Cancer Product

Table 51. GlaxoSmithKline Revenue in Hormonal Therapy for Cancer Business (2020-2025) & (US$ Million)

Table 52. GlaxoSmithKline Recent Development

Table 53. Jiangsu Haosen Company Details

Table 54. Jiangsu Haosen Business Overview

Table 55. Jiangsu Haosen Hormonal Therapy for Cancer Product

Table 56. Jiangsu Haosen Revenue in Hormonal Therapy for Cancer Business (2020-2025) & (US$ Million)

Table 57. Jiangsu Haosen Recent Development

Table 58. Sun Pharmaceutical Company Details

Table 59. Sun Pharmaceutical Business Overview

Table 60. Sun Pharmaceutical Hormonal Therapy for Cancer Product

Table 61. Sun Pharmaceutical Revenue in Hormonal Therapy for Cancer Business (2020-2025) & (US$ Million)

Table 62. Sun Pharmaceutical Recent Development

Table 63. Hengrui Medical Company Details

Table 64. Hengrui Medical Business Overview

Table 65. Hengrui Medical Hormonal Therapy for Cancer Product

Table 66. Hengrui Medical Revenue in Hormonal Therapy for Cancer Business (2020-2025) & (US$ Million)

Table 67. Hengrui Medical Recent Development

Table 68. Dr Reddy's Laboratories Company Details

Table 69. Dr Reddy's Laboratories Business Overview

Table 70. Dr Reddy's Laboratories Hormonal Therapy for Cancer Product

Table 71. Dr Reddy's Laboratories Revenue in Hormonal Therapy for Cancer Business (2020-2025) & (US$ Million)

Table 72. Dr Reddy's Laboratories Recent Development

Table 73. Astellas Pharma Company Details

Table 74. Astellas Pharma Business Overview

Table 75. Astellas Pharma Hormonal Therapy for Cancer Product

Table 76. Astellas Pharma Revenue in Hormonal Therapy for Cancer Business (2020-2025) & (US$ Million)

Table 77. Astellas Pharma Recent Development

Table 78. Sumitomo Pharma Company Details

Table 79. Sumitomo Pharma Business Overview

Table 80. Sumitomo Pharma Hormonal Therapy for Cancer Product

Table 81. Sumitomo Pharma Revenue in Hormonal Therapy for Cancer Business (2020-2025) & (US$ Million)

Table 82. Sumitomo Pharma Recent Development

Table 83. Johnson & Johnson Company Details

Table 84. Johnson & Johnson Business Overview

Table 85. Johnson & Johnson Hormonal Therapy for Cancer Product

Table 86. Johnson & Johnson Revenue in Hormonal Therapy for Cancer Business (2020-2025) & (US$ Million)

Table 87. Johnson & Johnson Recent Development

Table 88. Bayer AG Company Details

Table 89. Bayer AG Business Overview

Table 90. Bayer AG Hormonal Therapy for Cancer Product

Table 91. Bayer AG Revenue in Hormonal Therapy for Cancer Business (2020-2025) & (US$ Million)

Table 92. Bayer AG Recent Development

Table 93. Pfizer Company Details

Table 94. Pfizer Business Overview

Table 95. Pfizer Hormonal Therapy for Cancer Product

Table 96. Pfizer Revenue in Hormonal Therapy for Cancer Business (2020-2025) & (US$ Million)

Table 97. Pfizer Recent Development

Table 98. AstraZeneca Company Details

Table 99. AstraZeneca Business Overview

Table 100. AstraZeneca Hormonal Therapy for Cancer Product

Table 101. AstraZeneca Revenue in Hormonal Therapy for Cancer Business (2020-2025) & (US$ Million)

Table 102. AstraZeneca Recent Development

Table 103. Novartis Company Details

Table 104. Novartis Business Overview

Table 105. Novartis Hormonal Therapy for Cancer Product

Table 106. Novartis Revenue in Hormonal Therapy for Cancer Business (2020-2025) & (US$ Million)

Table 107. Novartis Recent Development

Table 108. Ferring Pharmaceuticals Company Details

Table 109. Ferring Pharmaceuticals Business Overview

Table 110. Ferring Pharmaceuticals Hormonal Therapy for Cancer Product

Table 111. Ferring Pharmaceuticals Revenue in Hormonal Therapy for Cancer Business (2020-2025) & (US$ Million)

Table 112. Ferring Pharmaceuticals Recent Development

Table 113. Myovant Sciences Company Details

Table 114. Myovant Sciences Business Overview

Table 115. Myovant Sciences Hormonal Therapy for Cancer Product

Table 116. Myovant Sciences Revenue in Hormonal Therapy for Cancer Business (2020-2025) & (US$ Million)

Table 117. Myovant Sciences Recent Development

Table 118. Research Programs/Design for This Report

Table 119. Key Data Information from Secondary Sources

Table 120. Key Data Information from Primary Sources

Table 121. Authors List of This Report

List of Figures

Figure 1. Hormonal Therapy for Cancer Picture

Figure 2. Global Hormonal Therapy for Cancer Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Hormonal Therapy for Cancer Market Share by Type: 2024 VS 2031

Figure 4. Tablet Features

Figure 5. Capsule Features

Figure 6. Injection Features

Figure 7. Others Features

Figure 8. Global Hormonal Therapy for Cancer Market Size by Application (2020-2031) & (US$ Million)

Figure 9. Global Hormonal Therapy for Cancer Market Share by Application: 2024 VS 2031

Figure 10. Hospital Case Studies

Figure 11. Retail Pharmacy Case Studies

Figure 12. Other Case Studies

Figure 13. Hormonal Therapy for Cancer Report Years Considered

Figure 14. Global Hormonal Therapy for Cancer Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 15. Global Hormonal Therapy for Cancer Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 16. Global Hormonal Therapy for Cancer Market Share by Region: 2024 VS 2031

Figure 17. Global Hormonal Therapy for Cancer Market Share by Players in 2024

Figure 18. Global Hormonal Therapy for Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 19. The Top 10 and 5 Players Market Share by Hormonal Therapy for Cancer Revenue in 2024

Figure 20. North America Hormonal Therapy for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. North America Hormonal Therapy for Cancer Market Share by Country (2020-2031)

Figure 22. United States Hormonal Therapy for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Canada Hormonal Therapy for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Europe Hormonal Therapy for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. Europe Hormonal Therapy for Cancer Market Share by Country (2020-2031)

Figure 26. Germany Hormonal Therapy for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. France Hormonal Therapy for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. U.K. Hormonal Therapy for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Italy Hormonal Therapy for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Russia Hormonal Therapy for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Ireland Hormonal Therapy for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Asia-Pacific Hormonal Therapy for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Asia-Pacific Hormonal Therapy for Cancer Market Share by Region (2020-2031)

Figure 34. China Hormonal Therapy for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Japan Hormonal Therapy for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. South Korea Hormonal Therapy for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Southeast Asia Hormonal Therapy for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. India Hormonal Therapy for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Australia & New Zealand Hormonal Therapy for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Latin America Hormonal Therapy for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Latin America Hormonal Therapy for Cancer Market Share by Country (2020-2031)

Figure 42. Mexico Hormonal Therapy for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Brazil Hormonal Therapy for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Middle East & Africa Hormonal Therapy for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Middle East & Africa Hormonal Therapy for Cancer Market Share by Country (2020-2031)

Figure 46. Israel Hormonal Therapy for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Saudi Arabia Hormonal Therapy for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. UAE Hormonal Therapy for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. GlaxoSmithKline Revenue Growth Rate in Hormonal Therapy for Cancer Business (2020-2025)

Figure 50. Jiangsu Haosen Revenue Growth Rate in Hormonal Therapy for Cancer Business (2020-2025)

Figure 51. Sun Pharmaceutical Revenue Growth Rate in Hormonal Therapy for Cancer Business (2020-2025)

Figure 52. Hengrui Medical Revenue Growth Rate in Hormonal Therapy for Cancer Business (2020-2025)

Figure 53. Dr Reddy's Laboratories Revenue Growth Rate in Hormonal Therapy for Cancer Business (2020-2025)

Figure 54. Astellas Pharma Revenue Growth Rate in Hormonal Therapy for Cancer Business (2020-2025)

Figure 55. Sumitomo Pharma Revenue Growth Rate in Hormonal Therapy for Cancer Business (2020-2025)

Figure 56. Johnson & Johnson Revenue Growth Rate in Hormonal Therapy for Cancer Business (2020-2025)

Figure 57. Bayer AG Revenue Growth Rate in Hormonal Therapy for Cancer Business (2020-2025)

Figure 58. Pfizer Revenue Growth Rate in Hormonal Therapy for Cancer Business (2020-2025)

Figure 59. AstraZeneca Revenue Growth Rate in Hormonal Therapy for Cancer Business (2020-2025)

Figure 60. Novartis Revenue Growth Rate in Hormonal Therapy for Cancer Business (2020-2025)

Figure 61. Ferring Pharmaceuticals Revenue Growth Rate in Hormonal Therapy for Cancer Business (2020-2025)

Figure 62. Myovant Sciences Revenue Growth Rate in Hormonal Therapy for Cancer Business (2020-2025)

Figure 63. Bottom-up and Top-down Approaches for This Report

Figure 64. Data Triangulation

Figure 65. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions